BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 12459940)

  • 1. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial.
    Kushida K; Fukunaga M; Kishimoto H; Shiraki M; Itabashi A; Inoue T; Kaneda K; Morii H; Nawata H; Yamamoto K; Ohashi Y; Orimo H
    J Bone Miner Metab; 2004; 22(5):469-78. PubMed ID: 15316868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis.
    Brown JP; Kendler DL; McClung MR; Emkey RD; Adachi JD; Bolognese MA; Li Z; Balske A; Lindsay R
    Calcif Tissue Int; 2002 Aug; 71(2):103-11. PubMed ID: 12085156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
    J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
    J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The clinical benefits to bone mineral density were shown by cyclical oral etidronate administration in steroid induced osteoporosis].
    Nakamura T; Maekawa S; Morinobu S; Morinobu A; Koshiba M; Yamauchi M; Sugimoto T; Kumagai S
    Ryumachi; 2002 Aug; 42(4):666-75. PubMed ID: 12355861
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Cohen S; Levy RM; Keller M; Boling E; Emkey RD; Greenwald M; Zizic TM; Wallach S; Sewell KL; Lukert BP; Axelrod DW; Chines AA
    Arthritis Rheum; 1999 Nov; 42(11):2309-18. PubMed ID: 10555025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: Results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study.
    Boonen S; Lorenc RS; Wenderoth D; Stoner KJ; Eusebio R; Orwoll ES
    Bone; 2012 Sep; 51(3):383-8. PubMed ID: 22750403
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study.
    Rosen CJ; Hochberg MC; Bonnick SL; McClung M; Miller P; Broy S; Kagan R; Chen E; Petruschke RA; Thompson DE; de Papp AE;
    J Bone Miner Res; 2005 Jan; 20(1):141-51. PubMed ID: 15619680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the Risedronate Late Phase II Research Group).
    Shiraki M; Fukunaga M; Kushida K; Kishimoto H; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H
    Osteoporos Int; 2003 May; 14(3):225-34. PubMed ID: 12730746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis.
    Delmas PD; McClung MR; Zanchetta JR; Racewicz A; Roux C; Benhamou CL; Man Z; Eusebio RA; Beary JF; Burgio DE; Matzkin E; Boonen S
    Bone; 2008 Jan; 42(1):36-42. PubMed ID: 17920005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
    Sato S; Takada T; Katsuki Y; Kimura N; Kaneko Y; Suwa A; Hirakata M; Kuwana M
    J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial.
    Hooper MJ; Ebeling PR; Roberts AP; Graham JJ; Nicholson GC; D'Emden M; Ernst TF; Wenderoth D
    Climacteric; 2005 Sep; 8(3):251-62. PubMed ID: 16390757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
    Sebaldt RJ; Ioannidis G; Adachi JD; Bensen WG; Bianchi F; Cividino A; Gordon M; Kaminska E; Scocchia T; Petrie A; Stephenson GF; Goldsmith CH
    J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of risedronate in osteoporotic postmenopausal women with inflammatory bowel disease: a prospective, parallel, open-label, two-year extension study.
    Palomba S; Manguso F; Orio F; Russo T; Oppedisano R; Sacchinelli A; Falbo A; Tolino A; Zullo F; Mastrantonio P
    Menopause; 2008; 15(4 Pt 1):730-6. PubMed ID: 18698280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
    Ettinger MP
    Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
    N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.